12 January 2021 in Nature Communications
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34+ cells and implanting autologous thymus in immune-deficient NOD-scid IL2Rγnull (NSG) mice. Reconstituted Hu-mice are challenged with HLA-matched melanomas and treated with anti-PD-1, which results in restricted tumor growth but not complete regression. Tumor RNA-seq, multiplexed imaging and immunohistology staining show high expression of chemokines, as well as recruitment of FOXP3+ Treg and mast cells, in selective tumor regions. Reduced HLA-class I expression and CD8+/Granz B+ T cells homeostasis are observed in tumor regions where FOXP3+ Treg and mast cells co-localize, with such features associated with resistance to anti-PD-1 treatment. Combining anti-PD-1 with sunitinib or imatinib results in the depletion of mast cells and complete regression of tumors. Our results thus implicate mast cell depletion for improving the efficacy of anti-PD-1 therapy.
1 September 2016 in Cell Host & Microbe
1 May 2020 in Clinical Cancer Research
Purpose: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer, which can be effectively controlled by immunotherapy with PD-1/PD-L1 checkpoint inhibitors. However, a significant proportion of patients are characterized by primary therapy resistance. Predictive biomarkers for response to immunotherapy are lacking. Experimental Design: We applied Bayesian inference analyses on 41 patients with MCC testing various clinical and biomolecular characteristics to predict treatment response. Further, we performed a comprehensive analysis of tumor tissue–based immunologic parameters including multiplexed immunofluorescence for T-cell activation and differentiation markers, expression of immune-related genes and T-cell receptor (TCR) repertoire analyses in 18 patients, seven objective responders, and 11 nonresponders. Results: Bayesian inference analyses demonstrated that among currently discussed biomarkers only unimpaired overall performance status and absence of immunosuppression were associated with response to therapy. However, in responders, a predominance of central memory T cells and expression of genes associated with lymphocyte attraction and activation was evident. In addition, TCR repertoire usage of tumor-infiltrating lymphocytes (TILs) demonstrated low T-cell clonality, but high TCR diversity in responding patients. In nonresponders, terminally differentiated effector T cells with a constrained TCR repertoire prevailed. Sequential analyses of tumor tissue obtained during immunotherapy revealed a more pronounced and diverse clonal expansion of TILs in responders indicating an impaired proliferative capacity among TILs of nonresponders upon checkpoint blockade. Conclusions: Our explorative study identified new tumor tissue–based molecular characteristics associated with response to anti–PD-1/PD-L1 therapy in MCC. These observations warrant further investigations in larger patient cohorts to confirm their potential value as predictive markers.
11 July 2024 in Journal of Medical Virology
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer associated with integration of Merkel cell polyomavirus (MCPyV). MCPyV‐encoded T‐antigens (TAs) are pivotal for sustaining MCC's oncogenic phenotype, i.e., repression of TAs results in reactivation of the RB pathway and subsequent cell cycle arrest. However, the MCC cell line LoKe, characterized by a homozygous loss of the RB1 gene, exhibits uninterrupted cell cycle progression after shRNA‐mediated TA repression. This unique feature allows an in‐depth analysis of the effects of TAs beyond inhibition of the RB pathway, revealing the decrease in expression of stem cell‐related genes upon panTA‐knockdown. Analysis of gene regulatory networks identified members of the E2F family (E2F1, E2F8, TFDP1) as key transcriptional regulators that maintain stem cell properties in TA‐expressing MCC cells. Furthermore, minichromosome maintenance (MCM) genes, which encodes DNA‐binding licensing proteins essential for stem cell maintenance, were suppressed upon panTA‐knockdown. The decline in stemness occurred simultaneously with neural differentiation, marked by the increased expression of neurogenesis‐related genes such as neurexins, BTG2, and MYT1L. This upregulation can be attributed to heightened activity of PBX1 and BPTF, crucial regulators of neurogenesis pathways. The observations in LoKe were confirmed in an additional MCPyV‐positive MCC cell line in which RB1 was silenced before panTA‐knockdown. Moreover, spatially resolved transcriptomics demonstrated reduced TA expression in situ in a part of a MCC tumor characterized by neural differentiation. In summary, TAs are critical for maintaining stemness of MCC cells and suppressing neural differentiation, irrespective of their impact on the RB‐signaling pathway.
4 February 2022 in bioRxiv
Background: Oral squamous cell carcinoma (OSCC), an HPV-negative head and neck cancer, frequently metastasizes to the regional lymph nodes but only occasionally beyond. Initial phases of metastasis are associated with an epithelial-mesenchymal transition (EMT), the consolidation phase is associated with mesenchymal-epithelial transition (MET). This dynamic is referred to as epithelial-mesenchymal plasticity (EMP). While it is known that EMP is essential for cancer cell invasion and metastatic spread, less is known about the heterogeneity of EMP states within a tumor and even less about the heterogeneity between the primary and metastatic lesions. Methods: To capture heterogeneity of EMP states in OSCC, we performed single-cell RNA sequencing (scRNAseq) of 5 primary tumors and 9 matching lymph node metastases and re-analyzed publicly available scRNAseq data of 9 additional primary tumors. To account for possible bias in cell type compositions by scRNAseq, these were also deconvoluted from bulk transcriptome analyses. Protein expression of selected genes were confirmed by immunohistochemistry. Results: From the 23 OSCC lesions the single cell transcriptome of a total of 7,263 carcinoma cells was available for in-depth analyses. We initially focused on one lesion to avoid inter-patient heterogeneity as a confounding factor and identified OSCC cells expressing genes characteristic of different epithelial and partial EMT stages, such as keratins and SPRR1B (cornifin B) or vimentin and matrix metallopeptidases. RNA velocity information together with the increase in inferred copy number variations indicated a progressive trajectory towards epithelial differentiation in this metastatic lesion. Extension to all samples revealed a less stringent but essentially similar pattern. Interestingly, cells undergoing MET show increased activity of the EMT activator ZEB1. Immunohistochemistry confirmed that ZEB1 was co-expressed with the epithelial marker cornifin B in individual tumor cells - more frequently in lymph node metastases. The lack of E-cadherin mRNA expression suggests this is a partial MET. Conclusions: This study reveals that EMP enables different partial EMT and epithelial phenotypes of OSCC cells, which are endowed with capabilities essential for the different stages of the metastatic process, including maintenance of cellular integrity. During MET, ZEB1 appears to be functionally active, indicating a more complex role of ZEB1 than mere induction of EMT.